Dr. Andrew Gaffney is the Director of Stem Cell Manufacturing and Commercialization at STEMCELL Technologies, where he oversees the development of human iPSCs, differentiated cells, and organoids. Andrew completed his PhD in pediatric oncology at the University of Leeds where he successfully established a human embryonic stem cell disease model of Ewing sarcoma. After joining STEMCELL in 2014, Andrew managed the company’s pluripotent stem cell product portfolio. He has also developed strategic alliances with stem cell scientists in academia and industry to support the development of PSC-based disease models, drug screens, and cell therapy applications.